| Literature DB >> 34011192 |
Mustfa K Manzur1, Andre M Samuel2, Kyle W Morse2, Karim A Shafi2, Bridget Jivanelli Gatto3, Catherine Himo Gang2, Sheeraz A Qureshi2, Sravisht Iyer2.
Abstract
STUDYEntities:
Keywords: direct decompression; indirect decompression; lateral approach; posterior instrumentation; spine fusion; systematic review
Year: 2021 PMID: 34011192 PMCID: PMC9344527 DOI: 10.1177/21925682211013011
Source DB: PubMed Journal: Global Spine J ISSN: 2192-5682
Review Inclusion/Exclusion Criteria.
|
|
| |
|---|---|---|
| Patient population | Age ≥18 years old Adjacent segment disease Degenerative disc disorders Degenerative scoliosis Low-grade spondylolisthesis Stenosis | Age <18 Years Old Revision Surgery Tumors Trauma Infection High-grade spondylolisthesis |
| Intervention | DLIF, LLIF, LIF, OLIF, or XLIF ± (stand-alone, PSF, and/or open decompression) | ALIF, AxiaLIF, PLIF, TLIF |
| Outcomes | Reported PROMs (VAS, ODI, SF-12/36), cross-sectional areas, vertebral angles, complications, revisions | Unreported outcomes |
| Level of evidence | I/II—RCT | Case reports |
| Publication types | English language | Letters & abstracts |
Abbreviations: ALIF, anterior lumbar interbody fusion; AxiaLIF, axial interbody fusion (Baxano Surgical, Raleigh, NC, USA); DLIF, direct lateral interbody fusion (Medtronic Sofamor Danek, Memphis, TN, USA); LIF, lateral interbody fusion; LLIF, lateral lumbar interbody fusion; ODI, Oswestry disability index; OLIF, oblique lumbar interbody fusion (Medtronic Sofamor Danek, Memphis, TN, USA); PLIF, posterior lumbar interbody fusion; PLF, posterior lumbar fusion; PROMs, patient reported outcomes measurements; SF-12, short form-12; SF-36, short form-36; TLIF, transforaminal lumbar interbody fusion; VAS, visual analog scale; XLIF, extreme lateral interbody fusion (NuVasive, San Diego, CA, USA).
Figure 1.Workflow for identifying included references. The systematic review workflow utilized in this review closely followed the PRISMA-P best-practice recommendations.
Demographics of Included Studies.
| Study | Subjects | Levels | Age (years) | BMI (kg/m2) | F/U Period (Months) | Duration (minutes) | Blood loss (mL) | LOS (Days) | Female % | Smoker % |
|---|---|---|---|---|---|---|---|---|---|---|
| Direct | ||||||||||
| Attenello et al, 201816 | 13 | 37 | 68.0 | NR | 21.0 | NR | NR | NR | 84.6% | 0.0% |
| Lee et al, 201617 | 21 | 113 | 67.1 | NR | 15.9 | 680.0 | 2127.1 | 24.6 | 81.3% | NR |
| Lim et al, 201914 | 8 | 11 | 66.0 | NR | 6.0 | NR | NR | 6.0 | 50.0% | 0.0% |
| Total or pooled mean |
|
|
|
|
|
|
|
|
|
|
| Standard deviation |
|
|
|
|
|
|
|
|
|
|
| Indirect | ||||||||||
| Ahmadian et al, 201310 | 31 | 31 | 61.5 | NR | 18.2 | NR | 94.0 | 3.5 | 71.0% | NR |
| Attenello et al, 201816 | 9 | 25 | 68.0 | NR | 24.0 | NR | NR | NR | 66.7% | 0.0% |
| Campbell et al, 20185 | 18 | 20 | 64.0 | 34.0 | 6.2 | 165.0 | 113.0 | NR | 61.0% | NR |
| Castellvi et al, 201411 | 44 | 117 | 66.0 | 29.4 | 12.0 | 410.0 | 217.0 | NR | 47.7% | NR |
| Fujibayashi et al, 201526 | 28 | 52 | 65.3 | NR | NR | 72.5 | 32.7 | NR | 64.3% | NR |
| Lee et al, 201617 | 11 | 59 | 67.1 | NR | 15.9 | 648.0 | 809.1 | 17.4 | 81.3% | NR |
| Lim et al, 201914 | 42 | 55 | 64.0 | NR | 6.0 | NR | NR | 3.0 | 60.0% | 16.7% |
| Lin et al, 20183 | 25 | 25 | 64.0 | 24.1 | 29.0 | 96.0 | 106.4 | 8.5 | 68.0% | 4.0% |
| Louie et al, 201828 | 25 | 100 | 61.9 | NR | 34.8 | 108.1 | 63.0 | 1.8 | 28.0% | 8.0% |
| Malham et al, 201613 | 40 | 40 | 58.5 | 28.3 | 34.1 | NR | NR | NR | 22.0% | 0.0% |
| Marchi et al, 201327 | 74 | 98 | 56.7 | 24.7 | 12.0 | 77.3 | 50.0 | NR | 64.9% | NR |
| Nemani et al, 20144 | 117 | 239 | 63.6 | 27.4 | 15.6 | 146.0 | 144.0 | NR | 70.9% | NR |
| Pereira et al, 201725 | 23 | 42 | 61.0 | NR | 12.0 | 222.0 | NR | 7.7 | 52.2% | 13.0% |
| Sato et al, 20171 | 20 | 20 | 69.0 | NR | 12.0 | NR | NR | NR | 55.0% | 10.0% |
| Scherman et al, 20192 | 50 | 84 | 68.2 | 29.0 | 25.2 | NR | NR | 6.9 | 62.0% | 10.0% |
| Total or pooled mean |
|
|
|
|
|
|
|
|
|
|
| Standard deviation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Abbreviations: BMI, body mass index; F/U, follow-up; LOS, average length of stay; NR, not reported.
* Significant difference.
Figure 2.Percentage of cases by indication. ASD, adjacent segment disorder, ADS, adult degenerative scoliosis, DDD, degenerative disc disease. Indication of cases varied by decompression approach.
Figure 3.Indirect decompression operative spinal segment levels. Operative spinal segment levels were generally located in the lumbar spine, most frequently involving L4-L5.
Lumbar Lordosis Radiological Measurements Reported.
| Direct | Indirect | ||||||
|---|---|---|---|---|---|---|---|
| Measurement | Mean | SD | Studies | Mean | SD | Studies | |
| Pre-Op lumbar lordosis | 22.8 | 8.9 | 2 | 41.9 | 9.1 | 8 | .09 |
| Post-Op lumbar lordosis | 48.7 | 8.0 | 2 | 45.5 | 9.4 | 8 | .38 |
| Lumbar lordosis difference | 25.9 | 16.9 | 2 | 3.7 | 2.8 | 8 | .18 |
| Lumbar lordosis difference % | 133.9% | 111.9% | 2 | 8.9% | 6.9% | 8 | .20 |
Abbreviations: Pre-Op, pre-operation; Post-Op, post-operation.
Patient-Reported Outcomes Measures of Included Studies.
| Direct | Indirect | ||||||
|---|---|---|---|---|---|---|---|
| Measurement | Mean | SD | # of studies | Mean | SD | # of studies | |
| ODI | |||||||
| Pre-Op ODI | 36.5 | 12.8 | 3 | 44.4 | 8.8 | 12 | .17 |
| Post-Op ODI | 19.4 | 10.3 | 3 | 23.1 | 8.3 | 12 | .30 |
| ODI difference | −17.1 | 3.5 | 3 | −21.3 | 7.2 | 12 | .05 ^ |
| VAS back pain | |||||||
| Pre-Op VAS back pain | 7.0 | 1.8 | 3 | 7.1 | 0.8 | 13 | .40 |
| Post-Op VAS back pain | 2.7 | 0.6 | 3 | 2.9 | 1.0 | 13 | .34 |
| VAS back pain difference | −4.3 | 1.5 | 3 | −4.2 | 0.9 | 13 | .46 |
| VAS leg pain | |||||||
| Pre-Op VAS leg pain | 4.9 | 2.9 | 2 | 6.8 | 1.6 | 8 | .37 |
| Post-Op VAS leg pain | 2.3 | 0.8 | 2 | 2.2 | 0.5 | 8 | .34 |
| VAS leg pain difference | −2.7 | 2.0 | 2 | −4.6 | 1.6 | 8 | .27 |
Abbreviations: ODI, Oswestry disability index; VAS, visual analog scale.
^ Insignificant Difference.
Post-Operative Clinical Indicators of Included Studies.
| Direct | Indirect | ||||||
|---|---|---|---|---|---|---|---|
| Measurement | Mean | SD | # of Studies | Mean | SD | # of studies | |
| Complication rate | 16.7% | 8.4% | 3 | 29.0% | 17.6% | 14 | .06 |
| Revision rate | 9.5% | 7.8% | 3 | 8.3% | 9.9% | 11 | .34 |
Newcastle-Ottawa Scale (NOS) Risk of Bias Scoring of Included Studies.
| Study | NOS selection | NOS comparable | NOS outcomes | NOS total | Risk of bias |
|---|---|---|---|---|---|
| Ahmadian et al, 201310 | 3 | 1 | 3 | 7 | Medium |
| Attenello et al, 201816 | 2 | 1 | 3 | 6 | Medium |
| Campbell et al, 20185 | 3 | 1 | 2 | 6 | Medium |
| Castellvi et al, 201411 | 3 | 2 | 3 | 8 | Low |
| Fujibayashi et al, 201526 | 3 | 2 | 2 | 7 | Medium |
| Lee et al, 201617 | 2 | 1 | 3 | 6 | Medium |
| Lim et al, 201914 | 3 | 1 | 2 | 6 | Medium |
| Lin et al, 20183 | 3 | 1 | 3 | 7 | Medium |
| Louie et al, 201828 | 3 | 1 | 3 | 7 | Medium |
| Malham et al, 201613 | 3 | 2 | 3 | 8 | Low |
| Marchi et al, 201327 | 3 | 2 | 3 | 8 | Low |
| Nemani et al, 20144 | 3 | 1 | 3 | 7 | Medium |
| Pereira et al, 201725 | 3 | 1 | 3 | 7 | Medium |
| Sato et al, 20171 | 3 | 1 | 3 | 7 | Medium |
| Scherman et al, 20192 | 3 | 1 | 3 | 7 | Medium |
| Average | 2.9 | 1.3 | 2.8 | 6.9 | Medium |